Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Single-blind, Randomized, Placebo-controlled Trial to Study the Efficacy and Safety of Anti-von Willebrand Factor Nanobody Administered as Adjunctive Treatment to Patients With Acquired Thrombotic Thrombocytopenic Purpura

Trial Profile

A Phase II, Single-blind, Randomized, Placebo-controlled Trial to Study the Efficacy and Safety of Anti-von Willebrand Factor Nanobody Administered as Adjunctive Treatment to Patients With Acquired Thrombotic Thrombocytopenic Purpura

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Caplacizumab (Primary) ; Caplacizumab (Primary)
  • Indications Thrombotic thrombocytopenic purpura
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Acronyms TITAN
  • Sponsors Ablynx
  • Most Recent Events

    • 14 Dec 2021 Results from TITAN, HERCULES and other studies, comparing patient-centered outcomes from Germany and Austria, presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 18 Feb 2021 Data from this study and HERCULES were used for cost-effective analysis of caplacizumab for immune thrombotic thrombocytopenic purpura, published in the Blood.
    • 04 Dec 2018 Results analysing integrated efficacy from the individual Phase II (TITAN) and III(HERCULES) studies with Caplacizumab in patients with Acquired Thrombotic Thrombocytopenic Purpura presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top